kvd001
Small moleculeexperimental
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 18, 2014 (NCT02193113)
Timeline
Indications
Studied for
Mechanism of action
- Kallikrein 2INHIBITOR
KLK2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- kvd001
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03466099 | Phase 2 | Feb 16, 2018 | KalVista Pharmaceuticals, Ltd. |
| NCT02193113 | Phase 1 | Jul 18, 2014 | Gulf Coast Eye Institute, Joslin Diabetes Center, Juvenile Diabetes Research Foundation, KalVista Pharmaceuticals, Ltd., Palmetto Retina Center, Retina-Vitreous Associates Medical Group |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| KalVista Pharmaceuticals, Ltd. | For profit | 2 | 2 | 2 | 2014 |
| Gulf Coast Eye Institute | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Joslin Diabetes Center | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Juvenile Diabetes Research Foundation | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Palmetto Retina Center | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Retina-Vitreous Associates Medical Group | Academic/Hospital | 1 | 0 | 1 | 2014 |
6 organizations
Page 1 / 1